KRAS
DiscoveriesLife-changing new drug revolutionizes pancreatic cancer treatment
The inhibitor targets the KRAS gene mutation, which is responsible for almost 90 percent of pancreatic cancers.
Joseph Shavit
The inhibitor targets the KRAS gene mutation, which is responsible for almost 90 percent of pancreatic cancers.
Joseph Shavit
